Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH
Status:
Active, not recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
To compare the safety, tolerability and LDL-C response after 24 Weeks of monthly (every 4
weeks [Q4W]) subcutaneous (SC) dosing of LIB003 300 mg with monthly (Q4W) SC dosing of 420 mg
evolocumab (Repatha®) in patients with HoFH on stable diet and oral LDL-C-lowering drug
therapy